Cargando…
Recent advances in understanding the role of glucagon-like peptide 1
The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment ba...
Autores principales: | Reed, Josh, Bain, Stephen C., Kanamarlapudi, Venkateswarlu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137394/ https://www.ncbi.nlm.nih.gov/pubmed/32269764 http://dx.doi.org/10.12688/f1000research.20602.1 |
Ejemplares similares
-
Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
por: Thompson, Aiysha, et al.
Publicado: (2016) -
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed, Josh, et al.
Publicado: (2021) -
The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression
por: Thompson, Aiysha, et al.
Publicado: (2014) -
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023) -
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)